![Bedrijf uit Retie dat polsbandjes maakt neemt labelspecialist Eurotag over (Retie) | Gazet van Antwerpen Mobile Bedrijf uit Retie dat polsbandjes maakt neemt labelspecialist Eurotag over (Retie) | Gazet van Antwerpen Mobile](https://static.gva.be/Assets/Images_Upload/2021/02/06/0de2dfba-b586-4b42-98a5-1d4494c5d6ab.jpg)
Bedrijf uit Retie dat polsbandjes maakt neemt labelspecialist Eurotag over (Retie) | Gazet van Antwerpen Mobile
![High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. - Abstract - Europe PMC High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8268616/bin/13073_2021_922_Fig4_HTML.jpg)
High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. - Abstract - Europe PMC
![Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study – ScienceOpen Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study – ScienceOpen](https://www.scienceopen.com/document_file/3d6ad591-0862-405a-9a86-5e9fea174cbf/PubMedCentral/large.png)
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study – ScienceOpen
![2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/32/Suppl_2/A51.1/F1.large.jpg)
2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer | International Journal of Gynecologic Cancer
![Els NIEUWENHUYSEN | Universitair Ziekenhuis Leuven, Leuven | UZ Leuven | Department of Gynaecology and obstetrics | Research profile Els NIEUWENHUYSEN | Universitair Ziekenhuis Leuven, Leuven | UZ Leuven | Department of Gynaecology and obstetrics | Research profile](https://www.researchgate.net/publication/353962339/figure/fig1/AS:1058034809839616@1629266564143/figure-fig1_Q320.jpg)